Exicure reports FY2024 net loss of $9.7M, cash $12.5M, going concern warning

EXICURE, INC.

Cash and cash equivalents $12.5M as of Dec 31, 2024, up from $0.8M year-end 2023; management warns liquidity may not last 12 months.
Net loss of $9.7M for FY2024, compared to net loss of $16.9M in FY2023; decrease driven by lower G&A and asset sale income.
R&D expenses $0 for FY2024 (from $1.4M) reflecting cessation of all R&D activities; G&A expenses $5.4M (from $11.7M).
Company continues exploring strategic alternatives, including transactions with potential partners; substantial doubt about going concern.
Sold clinical product samples and certain assets in 2024 to a private biopharma; no further operational details.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.